 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Therapeutic HIV Drug Monitoring
Overview
- Therapeutic Drug Monitoring: The Next Best Thing in HIV Treatment? (Fall 2002)
To read PDF, click here
In STEP Perspective, from Seattle Treatment Education Project - Pharmacology: Drug Level Monitoring and Beyond (July 2001)
To read PDF, click here
From Project Inform - Update on HIV Pharmacology and Therapeutic Drug Monitoring (July 2001)
From HIV InSite - Editorial: Putting an End to the Guesswork (February 2001)
In HIV Newsline, from San Francisco General Hospital - Optimal Medical Management: Clinical Considerations in Therapeutic Drug Monitoring (February 2001)
In HIV Newsline, from San Francisco General Hospital - Optimal Medical Management: Entering the Era of Truly Individualized Antiretroviral Therapy (February 2001)
In HIV Newsline, from San Francisco General Hospital - The Relevance of Pharmacologic Monitoring in HIV Disease (December 2000)
In The PRN Notebook
Research
- Drug Level Monitoring Nearly Doubles Likelihood of Reaching Target Levels (December 17, 2007)
From aidsmap.com - Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - New Research Explores Potential Value of Therapeutic Drug Monitoring (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Drug Monitoring and Pharmacology: More Mixes Nixed By Concentration Preoccupations (August 2004)
Highlights from a CROI 2004 post-conference workshop on drug-drug interactions.
In TAGline, from Treatment Action Group - Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network - To Measure or Not to Measure Drug Levels -- That Is the Question (March/April 2004)
Through the use of therapeutic drug monitoring, researchers are able to adjust patients' drug levels and reduce toxicity.
In Positively Aware, from Test Positive Aware Network - Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Importance of Resistance Testing and Therapeutic Drug Monitoring for Treatment Success (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Plasma Protease Inhibitor Levels Can Mark Nonadherence (January 23, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - A Population Based-Analysis of Amprenavir Trough Concentrations Assessed in the Course of Therapeutic Drug Monitoring (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Intracellular Metabolism of AZT Leads to the Production of Significant Levels of d4T Triphosphate in HIV Infected Patients (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Therapeutic Drug Monitoring: Does It Make a Difference? (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Hair Sample May Give Clues to HIV Drug Response (October 16, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - The Role of Therapeutic Drug Level Monitoring in Clinical Practice (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - HAART and the Management of HIV-1 Infection: Can Short-Term Changes in the Plasma HIV-1 RNA Level Predict Long-Term Response to Therapy? (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Therapeutic Drug Monitoring: A Must for Clinical Practice? (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Therapeutic Drug Monitoring (Summer/Autumn 2001)
Report on the 2nd International Workshop on Clinical Pharmacology in HIV Therapy.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - The CSF Concentration/IC50 Ratio: A Predictor of CNS Antiretroviral (ARV) Efficacy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Usefulness of Protease Inhibitor Therapeutic Drug Monitoring? PharmAdapt: A Prospective Multicentric Randomized Controlled Trial -- 12-Week Results (February 4, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  |
  |